Table of Contents
LECTURE 1: ALZHEIMER’S DISEASE ... 2
LECTURE 2: MOTOR NEURON DISEASE ... 6
LECTURE 3: PRION DISEASE ... 9
LECTURE 4: PARKINSON’S DISEASE ... 12
LECTURE 6: NEURODEVELOPMENTAL DISORDER ... 14
LECTURE 8: AUTISM SPECTRUM DISORDER ... 16
LECTURE 9: MODEL SYSTEM (NLGN1) ... 19
LECTURE 10: Type 2 Diabetes ... 21
LECTURE 11: ATHEROTHROMOSIS ... 25
LECTURE 12: LIPID METABOLISM ... 27
LECTURE 13: CARDIAC REGENERATION ... 30
LECTURE 16: System biology in cardiovascular disease ... 34
LECTURE 17: OBESITY ... 35
LECTURE 18: TYPE 1 DIABETES ... 37
LECTURE 19: RHEUMATOID ARTHRITIS ... 40
LECTURE 20: COVID FOG ... 43
LECTURE 21: Dengue Virus ... 48
LECTURE 22: ‘Horror autotoxicus’ ... 53
LECTURE 23: HTLV (human T-cell lymphotropic/leukemia virus) ... 55
LECTURE 24: Designer drugs/Clinical trials in oncology ... 58
LECTURE 25: Cancer immunotherapy ... 61
LECTURE 26: High throughput functional genomics technologies ... 64
LECTURE 27: Cancer Epigenetics ... 68
LECTURE 28: Tumour microenvironment ... 71
LECTURE 29: Tumour metastasis ... 74
LECTURE 3: PRION DISEASE
- Also known as Transmissible Spongiform Encephalopathies - Invariably fatal
- Neurodegenerative disorder - Long incubation period - Rapid progression
- Symptoms = hunched, ruffled, withdrawn, weight loss, ataxia, paresis Pathology:
- degeneration and death of neurons -> cleaved (activated) caspase 3 - accumulation of abnormal form of host encoded prion protein (PrP)
- Astrocytosis = both hypertrophy and hyperplasia of astrocytes in gray matter Aeitiology:
- Sporadic (85%)
o No known aetiology o CJD, GSS, sporadic FI
§ Strains of sporadic CJD
• PrPSc isolated from patient with CJD has different
electrophoretic mobility following PK digestion (different shape) -> indicative of strains of CJD
- Familial (15%)
o Mutation of prion protein gene
§ Gerstmann-Straussler-Scheinker (GSS)
• Motor incoordination
• Cerebellar ataxia
§ Creutzfeldt Jakob Disease (CJD)
• Rapidly progressive dementia
§ Fatal Familial Insomnia (FFI)
• Intractable insomnia - Acquired (rare)
o Iatrogenic (surgical) o Zoonotic
Discovering infectious agent:
- Protein only hypothesis:
o o Initially thought to be an exogenous agent… but later shown to be a post- translational modification of normal cellular protein
- PrP and prion transmission
o Absolute requirement of PrPC for transmission (prion protein knockout wont develop disease)
o Gene dosage effect
o Species specificity determined by sequence of prion protein gene
- Proving protein only hypothesis:
o Cell-free propagation of prion (PrPC + PrPSc -> PrPSc increase over time)
§ If given to knockout mouse… no conversion o Cell-free conversion assay
§ protein in presence of 50 fold excess of PrPSc derived from a prion- infected hamster
o RNA stimulated misfolding of mammalian PrPC -> prion disease
o RNA and lipid induced misfolding of recombinant PrP -> prion disease o Cell-free prions:
§ Propagation
• Partially prufieid PrPSc can induce conformational change in mammalian and recombinant PrPC
• Crude brain homogenates efficiently propagate prions
§ Infectivity
• Infectivity can be spontaneously generated from partially purified mammalian and recombinant PrPC
§ Efficient prion propagation requires PrPc and host derived ‘factors’
Pathogenesis:
- Prion protein (PrPC) misfolding -> PrPSc
o Protein sensitive, soluble, alpha-helix, many tissues, required for infection ->
protease resistant, insoluble, beta-sheet, disease specific, infectious o Physical association with clinical disease
o Major macromolecule which co-purifies with infectivity o Concentration of PrPSc is proportional to infectivity o Biophysical state correlates with infectivity profile o Mutations in PRNP linked to disease
- In presence of PrPSc, pathology only observed in tissue expressing PrPC - Despite presence of PrPSc, pathology can be reversed when PrPSc misfolding is
stopped by turning off/knocking down PrPC expression (RNAinterference targeting PrPC expression)
- Pathology is not observed when PrPSc propagation is not associated with membrane anchored PrPC (GPI-mice)
Prion strains:
- Characterised by:
o Clinical phenotype
o Where in brain damage occurs (lesion profile) o Incubation period
o Conformation of PrPSc
- Hyper strain (HY)
o Short incubation
o Brain stem and cerebellar cortex o Hyperactivity
- Drowsy strain (DY) o Long incubation
o Pyramidal layer adjacent to hippocampus o Lethargy (lack energy)
- HY VS DY = different conformation of PrPSc associated with strain variation o different electrophoretic mobility after PK digestion & FTIR spectroscopy
profile - Applications:
o Cofactors in sporadic disease o Diagnosis
o Treatment o Prevention Treatment:
- Poor clinical translation is due to:
o Short clinical duration
o Limitations of pre-clinical diagnosis o Strain variation
- Anti-sense oligo (ASO) therapeutics:
o Alter function of target RNA
o Decrease total protein (therapeutic target for disease caused by single protein)… however, depletion of PrPC induce cancer